LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Начало・Списък с акции・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Затворен

СекторЗдравеопазване

168.66 -1.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

167.72

Максимум

174.52

Ключови измерители
By Trading Economics
Приходи	2.9M 56M
Продажби	-27M 1B
P/E Средно за сектора	592.3 105.69
EPS	2.43
Марж на печалбата	5.529
Служители	18,700
EBITDA	-23M 198M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+11.95% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-487M 8.3B
Предишно отваряне	170.26
Предишно затваряне	168.66

Настроения в новините

By Acuity

21%

79%

49 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

117.16 / 144.77 Подкрепа & съпротива

Charles River Laboratories International Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.11.2025 г., 21:34 ч. UTC

Печалби

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13.11.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13.11.2025 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13.11.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13.11.2025 г., 23:24 ч. UTC

Печалби

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13.11.2025 г., 23:24 ч. UTC

Печалби

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13.11.2025 г., 23:23 ч. UTC

Печалби

JBS NV 3Q EPS 52c >JBS

13.11.2025 г., 23:23 ч. UTC

Печалби

JBS NV 3Q Sales $22.6B >JBS

13.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13.11.2025 г., 22:02 ч. UTC

Печалби

Nu Holdings 3Q Net $783M >NU

13.11.2025 г., 22:01 ч. UTC

Печалби

Nu Holdings 3Q Rev $4.2B >NU

13.11.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13.11.2025 г., 21:50 ч. UTC

Печалби

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13.11.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13.11.2025 г., 21:41 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13.11.2025 г., 21:33 ч. UTC

Пазарно говорене

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13.11.2025 г., 21:33 ч. UTC

Печалби

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13.11.2025 г., 21:31 ч. UTC

Печалби

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13.11.2025 г., 21:25 ч. UTC

Печалби

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13.11.2025 г., 21:25 ч. UTC

Печалби

Figure Tech Solutions 3Q EPS 34c >FIGR

13.11.2025 г., 21:23 ч. UTC

Печалби

Intchains Group 3Q Rev $1.3M >ICG

13.11.2025 г., 21:03 ч. UTC

Печалби

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13.11.2025 г., 21:02 ч. UTC

Печалби

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13.11.2025 г., 21:01 ч. UTC

Печалби

Applied Materials 4Q Rev $6.8B >AMAT

13.11.2025 г., 21:01 ч. UTC

Печалби

Applied Materials 4Q Gross Margin 48.0% >AMAT

Сравнение с други в отрасъла

Ценова промяна

Charles River Laboratories International Inc Прогноза

Ценова цел

By TipRanks

11.95% нагоре

12-месечна прогноза

Среден 192 USD 11.95%

Висок 225 USD

Нисък 165 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Charles River Laboratories International Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Charles River Laboratories International Inc през последните 3 месеца.

Техническа оценка

By Trading Central

117.16 / 144.77Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

49 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.